Hong Kong Stocks Movement | Select Pharmaceutical Stocks Rally in Afternoon Session: CANSINOBIO (06185) Surges Over 10%, JUNSHI BIO (01877) Gains Over 5%

Stock News01-26

Selected pharmaceutical stocks experienced a notable uptick during the afternoon trading session. At the time of writing, CANSINOBIO (06185) surged by 10.13%, reaching HK$40.86; JUNSHI BIO (01877) climbed 5.19%, trading at HK$23.92; and FUDANZHANGJIANG (01349) advanced 4.11%, quoted at HK$3.29. The rally appears to be linked to news that emerged on January 26th, where topics concerning a Nipah virus outbreak in India gained significant traction online, drawing widespread attention. According to reports, a Nipah virus outbreak has been confirmed in India, prompting neighboring countries to heighten their alert levels. Confirmed infections are primarily concentrated in the Indian state of West Bengal. As of this report, the number of confirmed cases has reached five, with at least one patient in critical condition, and approximately one hundred individuals have been instructed to undergo home quarantine. Public information indicates that Nipah is a zoonotic RNA virus, primarily carried by fruit bats and pigs, with a mortality rate ranging from 40% to 75% and an incubation period typically between 4 and 14 days. Currently, there are no specific vaccines or effective treatments available for the Nipah virus; medical efforts focus on managing symptoms and providing supportive care.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment